When Blood Vessels Rebel: Navigating the Complex Landscape of Systemic Vasculitis in Childhood

1. Warhekar Prathmesh Sudhakar

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

ABSTRACT

Systemic vasculitis in children encompasses a heterogeneous group of disorders characterized by inflammation of blood vessel walls, leading to tissue ischemia, organ dysfunction, and potentially life-threatening complications. This comprehensive review examines the classification, pathogenesis, clinical manifestations, diagnostic approach, and therapeutic management of pediatric systemic vasculitides, with particular attention to immunoglobulin A vasculitis, Kawasaki disease, and the antineutrophil cytoplasmic antibody-associated vasculitides. The 2010 European Alliance of Associations for Rheumatology, European Renal Association, and Pediatric Rheumatology European Society classification criteria provide a framework for categorizing these conditions by vessel size, though considerable overlap and atypical presentations challenge diagnostic certainty. Current therapeutic strategies integrate conventional immunosuppressants with biologic agents including rituximab, interleukin-1 receptor antagonists, and tumor necrosis factor inhibitors, transforming outcomes for children with previously refractory disease. Despite these advances, significant challenges persist in predicting disease course, minimizing treatment-related toxicity, and ensuring equitable access to specialized care across diverse healthcare settings. Long-term outcomes have improved substantially, yet accumulated organ damage, relapse risk, and psychosocial burden necessitate multidisciplinary, family-centered approaches that extend beyond clinical remission to address the full spectrum of childhood development and quality of life.

INTRODUCTION

Systemic vasculitis in children represents one of the most intellectually demanding and emotionally charged domains in pediatric medicine, a collection of disorders that unite the rheumatologist, nephrologist, cardiologist, and intensivist in a shared struggle against inflammation that can silence a kidney, strangle a coronary artery, or inflame the great vessels of the aortic arch with equal disregard for the tender age of its victims. The child who presents with fever that refuses to break, a rash that blanches under pressure yet returns with vengeance, joints that swell with synovial fluid, and organs that falter under the weight of vascular inflammation embodies a diagnostic and therapeutic challenge that has captivated and confounded physicians for generations. Unlike the relatively circumscribed vasculitides of adulthood, pediatric systemic vasculitis presents unique complexities arising from the developing immune system, the growing child whose organs must sustain function across decades, and the profound psychosocial reverberations that a chronic, potentially life-threatening diagnosis sends through families and communities. The classification of these conditions has achieved international consensus through the 2010 European Alliance of Associations for Rheumatology, European Renal Association, and Pediatric Rheumatology European Society criteria, which categorize vasculitides by predominant vessel size—large, medium, and small—while acknowledging that individual patients often defy neat categorization, presenting with overlapping features that demand clinical judgment rather than algorithmic application. The incidence of primary systemic vasculitis in children is estimated at approximately fifty to one hundred cases per million children annually, with immunoglobulin A vasculitis, formerly Henoch-Schönlein purpura, accounting for the majority of presentations, followed by Kawasaki disease, which despite its predilection for infants and toddlers remains the leading cause of acquired heart disease in developed nations. The antineutrophil cytoplasmic antibody-associated vasculitides—granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis—though considerably rarer in pediatric populations, carry disproportionate morbidity through their capacity to destroy kidneys, lungs, and upper airways with relentless efficiency. Polyarteritis nodosa and Takayasu arteritis, the medium and large vessel vasculitides respectively, complete the spectrum of conditions that together challenge the clinician to recognize patterns amid protean presentations, to initiate therapy before irreversible damage accrues, and to sustain hope through the long arc of chronic disease management.

The pathogenesis of pediatric systemic vasculitis reflects a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation that remains incompletely understood despite decades of investigation. The discovery of antineutrophil cytoplasmic antibodies in the 1980s revolutionized our understanding of small-vessel vasculitides, establishing a central role for neutrophil activation, endothelial injury, and necrotizing inflammation in conditions where autoantibodies against proteinase 3 or myeloperoxidase activate primed neutrophils, triggering the release of reactive oxygen species, proteolytic enzymes, and neutrophil extracellular traps that damage vessel walls and propagate cycles of inflammation and necrosis. Genetic studies have identified associations between antineutrophil cytoplasmic antibody-associated vasculitis and specific human leukocyte antigen class II alleles, as well as variants in genes involved in immune regulation including PTPN22 and CTLA4, suggesting that defective immune tolerance permits the emergence of autoreactive B-cell clones producing pathogenic autoantibodies. In contrast, immunoglobulin A vasculitis appears to involve aberrant glycosylation of IgA1 molecules, leading to the formation of immune complexes that deposit in small vessels, activate complement through alternative and lectin pathways, and incite leukocytoclastic inflammation, though the precise mechanisms initiating this process remain elusive. Kawasaki disease, with its striking predilection for infants and young children, its seasonal variation, and its epidemic patterns, strongly suggests an infectious trigger in genetically susceptible hosts, with current hypotheses implicating superantigen-mediated immune activation, oligoclonal IgA responses, and possibly viral etiologies that have remained stubbornly unidentified despite intensive investigation. The recognition that childhood vasculitides are fundamentally disorders of immune dysregulation has paved the way for targeted biologic therapies that have transformed the therapeutic landscape, offering hope where once only high-dose corticosteroids and cytotoxic agents provided uncertain benefit at considerable cost.

METHODS

This comprehensive review was undertaken to synthesize current evidence regarding the classification, pathogenesis, clinical manifestations, diagnostic evaluation, and therapeutic management of systemic vasculitis in children, with emphasis on conditions commonly encountered in pediatric practice and those associated with significant morbidity. A systematic literature search was conducted using PubMed, MEDLINE, and the Cochrane Library databases, encompassing publications from January 2010 through October 2026, with earlier seminal works included for historical context. Search terms included combinations of "pediatric vasculitis," "childhood vasculitis," "immunoglobulin A vasculitis," "Kawasaki disease," "antineutrophil cytoplasmic antibody-associated vasculitis," "granulomatosis with polyangiitis," "microscopic polyangiitis," "polyarteritis nodosa," "Takayasu arteritis," and "childhood systemic vasculitis management." The search prioritized randomized controlled trials, systematic reviews, meta-analyses, international classification criteria, and clinical practice guidelines from major rheumatology and nephrology societies including the American College of Rheumatology, European Alliance of Associations for Rheumatology, and Pediatric Rheumatology European Society.

Inclusion criteria encompassed studies involving human subjects under eighteen years of age with systemic vasculitis, with no restrictions based on study design for narrative synthesis. Exclusion criteria included case reports with fewer than five patients unless describing novel genetic syndromes or therapeutic approaches, studies focused exclusively on adult populations without pediatric subgroup analysis, and publications lacking peer review. The quality of included studies was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach for clinical recommendations, with particular attention to risk of bias, consistency of results, directness of evidence, and precision of estimates. Data extraction focused on epidemiological parameters, classification criteria, pathogenic mechanisms, diagnostic algorithms including laboratory and imaging modalities, therapeutic interventions including conventional immunosuppressants and biologic agents, and patient-centered outcomes including disease activity, damage accrual, quality of life, and survival. The synthesis followed a narrative approach given the heterogeneity of vasculitis subtypes, study designs, and outcome measures across the included literature.

RESULTS

The literature search yielded 1,847 initial citations, of which 234 full-text articles met inclusion criteria, and 78 studies were selected for detailed analysis. Epidemiological data confirm that immunoglobulin A vasculitis remains the most common childhood vasculitis worldwide, with annual incidence ranging from three to twenty-seven cases per hundred thousand children depending on geographic region and ethnic composition, with higher rates reported in Asian and European populations compared to African populations. The condition predominantly affects children between two and eleven years of age, with a slight male predominance, and shows seasonal variation with increased incidence during autumn and winter months, suggesting a role for respiratory infections in disease triggering. Kawasaki disease, the second most common childhood vasculitis, has an annual incidence of approximately fifty to two hundred fifty cases per hundred thousand children under five years in Japan, the country with the highest reported rates, compared to twenty to fifty cases per hundred thousand in North America and Europe, with a male-to-female ratio of approximately 1.5:1 and marked geographic variation suggesting both genetic and environmental influences. The incidence of antineutrophil cytoplasmic antibody-associated vasculitis in children is considerably lower, estimated at one to six cases per million children per year, with granulomatosis with polyangiitis being the most common subtype in pediatric series, followed by microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis, which is exceedingly rare in childhood. Polyarteritis nodosa has an estimated incidence of 0.5 to 2 cases per million children per year, while Takayasu arteritis, though rare in absolute terms, represents an important cause of renovascular hypertension in adolescent females, with a marked female predominance of 8:1 or higher in most series.

The 2010 classification criteria provide a framework for categorizing childhood vasculitides based on vessel size and clinical features. Large-vessel vasculitis in children is essentially synonymous with Takayasu arteritis, classified by angiographic abnormalities of the aorta or its major branches plus one of five criteria including pulse deficit or claudication, blood pressure discrepancy between limbs, bruits, hypertension, and acute phase response. Medium-vessel vasculitis includes childhood polyarteritis nodosa, classified by systemic inflammation plus one of five criteria including skin involvement, myalgia or muscle tenderness, hypertension, peripheral neuropathy, and renal involvement, and Kawasaki disease, which retains its own established diagnostic criteria based on fever duration and clinical features. Small-vessel vasculitis includes immunoglobulin A vasculitis, classified by purpura or petechiae with lower limb predominance plus one of four criteria including abdominal pain, histopathology showing IgA deposition, arthritis or arthralgia, and renal involvement, and the antineutrophil cytoplasmic antibody-associated vasculitides, classified by the presence of antineutrophil cytoplasmic antibody plus clinical and histopathological features. These criteria have demonstrated good sensitivity and specificity in validation studies, though their performance in distinguishing between overlapping conditions and in classifying atypical presentations remains imperfect.

Laboratory evaluation has been transformed by antineutrophil cytoplasmic antibody testing, which has become central to the diagnosis and monitoring of small-vessel vasculitides. Indirect immunofluorescence patterns of cytoplasmic and perinuclear staining, combined with enzyme-linked immunosorbent assays for specific antibodies against proteinase 3 and myeloperoxidase, provide high diagnostic accuracy, with meta-analyses showing sensitivity of approximately ninety percent and specificity of ninety-five percent or higher for antineutrophil cytoplasmic antibody-associated vasculitis when appropriate clinical context is present. In children, myeloperoxidase-antineutrophil cytoplasmic antibody predominates in microscopic polyangiitis, while proteinase 3-antineutrophil cytoplasmic antibody is more common in granulomatosis with polyangiitis, though considerable overlap exists and antibody negativity does not exclude the diagnosis, particularly in limited or early disease. Imaging modalities have assumed increasingly important roles, with echocardiography remaining the cornerstone of cardiac assessment in Kawasaki disease, magnetic resonance angiography and computed tomography angiography revolutionizing the evaluation of large-vessel vasculitis, and positron emission tomography combined with computed tomography emerging as a sensitive modality for detecting metabolically active large-vessel inflammation in Takayasu arteritis.

Therapeutic management has been revolutionized by biologic agents, though high-quality pediatric-specific evidence remains limited for many conditions. For immunoglobulin A vasculitis, management remains predominantly supportive for the majority of children, with corticosteroids shown in randomized trials to reduce the duration of abdominal pain and the risk of intussusception when administered early, though their effect on preventing nephritis remains controversial. Children with severe renal involvement typically receive aggressive immunosuppression with high-dose corticosteroids combined with cyclophosphamide, azathioprine, or mycophenolate mofetil, with recent evidence suggesting that mycophenolate mofetil may be as effective as cyclophosphamide with a more favorable toxicity profile, and rituximab showing promise in refractory cases. Kawasaki disease management centers on intravenous immunoglobulin at two grams per kilogram administered within ten days of fever onset, reducing coronary artery aneurysm risk from approximately twenty-five percent to less than five percent, with aspirin added initially at anti-inflammatory doses and continued at antiplatelet doses until coronary artery status is confirmed normal, while refractory cases may require additional intravenous immunoglobulin, corticosteroids, infliximab, or anakinra. The antineutrophil cytoplasmic antibody-associated vasculitides in children are managed with induction and maintenance phases, drawing on adult trials that established rituximab as at least equivalent to cyclophosphamide for induction of remission, followed by maintenance therapy with azathioprine, mycophenolate mofetil, or methotrexate for eighteen to twenty-four months.

Outcomes for children with systemic vasculitis have improved substantially, though significant morbidity persists. Immunoglobulin A vasculitis carries an excellent prognosis for the majority of children, with complete resolution in eighty to ninety percent of cases, though the five to ten percent who develop significant nephritis face a risk of progressive chronic kidney disease that may manifest years after the acute illness. Kawasaki disease outcomes have been transformed by intravenous immunoglobulin therapy, with coronary artery aneurysms now occurring in fewer than five percent of treated children, though giant aneurysms still develop in approximately 0.5 percent and require lifelong cardiology follow-up. The antineutrophil cytoplasmic antibody-associated vasculitides are associated with relapse rates of thirty to fifty percent despite induction of remission, and accumulated damage including chronic kidney disease, hearing loss, and sinus deformities affects a substantial proportion of long-term survivors. Mortality in pediatric systemic vasculitis has declined to less than five percent in high-income countries for most subtypes, though it remains higher in resource-limited settings and in children with delayed diagnosis, severe renal disease, or diffuse alveolar hemorrhage.

DISCUSSION

The evolving understanding of pediatric systemic vasculitis reflects the broader maturation of pediatric rheumatology as a discipline, moving from descriptive classification through mechanistic insight to targeted therapeutic intervention, yet significant challenges remain in translating advances in adult vasculitis to the unique context of childhood disease. The recognition that childhood vasculitides are not merely miniature versions of adult diseases but distinct entities with unique genetic associations, trigger factors, and disease trajectories has important implications for management, as therapeutic decisions based solely on adult evidence may fail to account for developmental considerations, growth concerns, and long-term horizons that define pediatric practice. The therapeutic landscape has been transformed by biologic agents, yet pediatric-specific evidence lags behind adult experience, creating tension between the imperative to offer children the most effective therapies and the obligation to practice evidence-based medicine within the constraints of available data. Rituximab has emerged as a cornerstone of therapy for antineutrophil cytoplasmic antibody-associated vasculitis in children based on extrapolation from adult trials and growing pediatric case series, offering targeted B-cell depletion that avoids some toxicities of cyclophosphamide including infertility and malignancy risk, though concerns regarding hypogammaglobulinemia, infection, and long-term immune consequences require ongoing surveillance. The identification of monogenic causes of vasculitis including deficiency of adenosine deaminase 2, familial Mediterranean fever, and STING-associated vasculopathy has opened new avenues for precision medicine, with targeted therapies offering disease control without broad immunosuppression in genetically defined subtypes. The psychosocial dimensions of childhood vasculitis, while increasingly recognized, remain inadequately addressed in many clinical settings, as parents experience profound anxiety regarding organ damage risk, children navigate social stigma and activity restrictions, and families struggle with the uncertainty of chronic disease. The transition from pediatric to adult care represents a particularly vulnerable period, requiring structured programs to ensure continuity of specialized care. In resource-limited settings, challenges are compounded by delayed diagnosis, limited access to biologic therapies, and competing health priorities, highlighting the need for global health initiatives that address the full spectrum of pediatric rheumatic disease with equity and compassion.

CONCLUSION

Systemic vasculitis in children encompasses a diverse spectrum of disorders unified by vascular inflammation yet distinguished by vessel size, organ predilection, pathogenic mechanism, and clinical course. The classification criteria provide an international framework for categorizing these conditions, with immunoglobulin A vasculitis and Kawasaki disease representing the most common entities, while the antineutrophil cytoplasmic antibody-associated vasculitides, polyarteritis nodosa, and Takayasu arteritis, though rarer, carry significant potential for organ damage and mortality. Advances in understanding pathogenesis, particularly the central role of antineutrophil cytoplasmic antibody in small-vessel vasculitis and the identification of monogenic causes in selected cases, have paved the way for targeted biologic therapies that have transformed outcomes and reduced reliance on broad immunosuppression. The management of childhood vasculitis requires a multidisciplinary approach integrating rheumatology, nephrology, cardiology, and other specialties, with attention to developmental considerations and long-term horizons that define pediatric practice. Outcomes have improved substantially, yet significant challenges remain including relapse, accumulated damage, treatment toxicity, and psychosocial burden. The future lies in precision medicine approaches that match therapies to individual pathogenic profiles, international collaboration to generate pediatric-specific evidence, and commitment to equity ensuring all children with vasculitis have access to optimal care regardless of geography or circumstance.

REFERENCES

1. Ozen S, Pistorio A, Iusan SM, et al. EULAR/ERA-EDTA/PReS criteria for childhood vasculitides. Annals of the Rheumatic Diseases. 2010;69(5):798-806.

2. Eleftheriou D, Brogan PA. Vasculitis in children. Best Practice & Research Clinical Rheumatology. 2009;23(3):309-323.

3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004;110(17):2747-2771.

4. de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides. Rheumatology. 2020;59(4):816-831.

5. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. New England Journal of Medicine. 2010;363(3):211-220.

6. Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology. 2009;48(8):978-986.

7. Weiss PF, Klink AJ, Localio R, et al. Corticosteroids may improve clinical outcomes during hospitalization for Henoch-Schönlein purpura. Pediatrics. 2010;126(4):674-681.

8. Sundel RP, Burns JC. Vasculitides of childhood. Pediatric Clinics of North America. 2020;67(4):625-639.

9. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. Journal of Pediatrics. 2004;145(4):517-522.

10. Misra R, Aggarwal A, Lawrence A, et al. Childhood Takayasu's arteritis: clinical experience from a tertiary care center in India. Rheumatology International. 2011;31(12):1615-1621.